Analyst Price Target is $17.67
▲ +7,417.73% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cellectar Biosciences in the last 3 months. The average price target is $17.67, with a high forecast of $28.00 and a low forecast of $12.00. The average price target represents a 7,417.73% upside from the last price of $0.24.
Current Consensus is
Moderate Buy
The current consensus among 3 investment analysts is to moderate buy stock in Cellectar Biosciences. This rating changed within the last month from a Buy consensus rating.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Read More
